Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE: Perioperative Nivolumab and Relatlimab in Gastric/AEG Cancer
NCT04062656Phase 2Unknown
- Sponsor
- Universitätsmedizin Essen
- Start
- Sep 2019
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric cancer (GC) and adenocarcinoma of the esophagogastric junction (AEG) comparing Arm B: Nivolumab with Arm D: Nivolumab + Relatlimab (2 arms). Primary endpoint: Pathological Complete Response Rate at 3 years. Status: unknown.
02
Drugs
relatlimabnivolumab
03
Conditions
gastric cancer (GC)adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT04062656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062656.